SLC7A11 and neoplasm: These two characteristics of SLC7A11, namely its dispensability in normal physiology and its high expression in cancers, suggest that targeting SLC7A11 likely can selectively kill tumor cells and impair tumor growth while sparing normal cells or tissues, therefore nominating SLC7A11 as a promising therapeutic target in cancer treatment.